JNJ-5939

N/A

Report date: 2025/12/30 20:00:13
First In Class

Base Information

Drug NameJNJ-5939
Drug Alias NameNM26-2198JNJ-5939NM-26JNJ-95475939
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitorsInterleukin-31 inhibitorsInterleukin-13 inhibitors
TargetsInterleukin-4 receptor subunit alphaInterleukin-31Interleukin-13
Therapy Area/IndicationsInflammationDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNumab Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development LlcNumab Therapeutics AgKaken Pharmaceutical Co Ltd
Inactive CompaniesYellow Jersey Therapeutics AG
Active IndicationsDermatitis, Atopic
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A